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Acquired middle ear cholesteatoma is a benign keratinizing hyperproliferative squamous epithe-
lial lesion that may result in the destruction of the bone structures surrounding the temporal bone. 
Recent studies show that variations in cellular production of matrix metalloproteinases (MMPs) and 
their specific inhibitors (TIMPs) contribute to the pathophysiology of cholesteatoma.
Objective: This study aims to analyze the use of RNA amplification tests to evaluate the expression 
of MMP and TIMP isoforms in cholesteatomas and their correlation with disease severity.
Materials and Methods: This is a prospective study. Nineteen cholesteatoma cases at different 
stages were selected. RNA collected from biopsy specimens was submitted to reverse transcription 
polymerase chain reaction (RT-PCR) for semiquantitative amplification of MMP2, MMP3, MMP9, 
MMP13 and TIMP1.
Results: Six cholesteatomas were positive for at least one of the studied genes. Four samples ampli-
fied a single gene (MMP2 or MMP13) and two samples amplified three genes (MMP2, TIMP1 and 
MMP3 or MMP13). No sample amplified MMP9.
Conclusion: RT-PCR can be used to assess MMP and TIMP gene expression in cholesteatomas 
despite technical difficulties. Gene expression profiles could not be related to disease severity.
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INTRODUCTION
Middle-ear acquired cholesteatoma is a benign 
squamous epithelial keratinizing hyperproliferative le-
sion resembling the epidermis1 that develops inside the 
tympanic cavity2-4. It manifests as a type of epidermoid 
cyst with an extracellular matrix made up of squamous 
stratified keratinized epithelium over a secondary peri-
matrix containing collagen and elastic fibers, fibroblasts, 
and inflammatory cells5,6. Middle-ear cholesteatomas are 
characterized by intense cell proliferation - accompanied 
by the consequent accumulation of keratin debris - and 
destruction of bone structures surrounding the tempo-
ral bone. They may involve the ossicles, blood vessels, 
the facial nerve, and even invade the inner ear and 
intracranial space7-9. Cholesteatomas may lead to the 
onset of hearing loss, tinnitus, vertigo, loss of balance, 
and other severe complications such as meningitis, 
sigmoid sinus thrombosis, facial paralysis, and brain 
abscess2.
It has recently become evident that the proteolytic 
activity triggered by cholesteatomas plays a key role in 
the bone remodeling of the middle ear and the temporal 
bone10. Bone lysis and recurrence are relevant features 
in the pathophysiology of cholesteatoma, giving it the 
status of a dangerous, difficult-to-treat condition11. Alte-
rations in keratinocyte proliferation, differentiation, and 
migration are impacted by fibroblast activation in the 
perimatrix and by the release of cytokines and growth 
factors by inflammatory infiltrate cells4,12.
Injury to tissues adjacent to cholesteatomas also 
occurs due to the action of various proteolytic enzymes 
such as plasminogen activators and matrix metalloprotei-
nases (MMPs)3,7. MMPs are zinc and calcium-dependent 
endopeptidases synthesized by different types of cells 
such as fibroblasts, keratinocytes, macrophages, and 
endothelial cells activated by proteolytic cleavage8,10,13-16. 
MMP proteolytic activity is precisely controlled by their 
precursors during activation and inhibited by endo-
genous inhibitors, alpha macroglobulins, and tissue 
inhibitors of metalloproteinases (TIMPs)8,17. The balance 
between MMPs and TIMPs is critical in determining the 
integrity of the extracellular matrix (ECM); thus, the va-
riations in presence and activity level of these proteins 
may contribute in a number of tissue events observed 
in cholesteatoma patients3,8,17.
Specific cholesteatoma MMP isoenzymes (MMP2, 
MMP3, and MMP9) were first identified in 199617 with the 
use of immunohistochemistry tests. Since then, immuno-
histochemistry has been extensively used to analyze and 
compare changes in enzyme levels in cholesteatomas and 
healthy tissues. Increased levels of MMP97,10,11,14, MMP25, 
MMP118, MMP8 and MMP1319 have been reported. Im-
mune labeling of MMP2, 3 and 9 was observed mainly 
in the basal and suprabasal layers of the cholesteatoma 
epithelium10,14,17; MMP9 was specifically seen in areas 
with inflammatory cell infiltration8.
This study aims to analyze the applicability of 
reverse transcription polymerase chain reaction (RT-
-PCR) to semiquantitatively assess gene expression 
in matrix metalloproteinases and their inhibitors. 
If RT-PCR is proven adequate, we will attempt to cor-
relate gene expression to disease severity based on the 
patients’ clinical history, audiometric assessment, and 
imaging findings.
MATERIALS AND METHODS
This is a prospective study designed to offer the 
basis required to reach the proposed goals and additio-
nal information on the topic, aside from aiding in the 
identification of the determining factors connected to 
the phenomena and events described herein20. Nineteen 
patients aged between 5 and 70 years diagnosed with 
various stages of chronic cholesteatomatous otitis media 
were enrolled in this study. They were seen and ope-
rated at the institution’s ENT ward from 2007 to 2009. 
Patients previously submitted to mastoidectomy and with 
unconfirmed diagnosis of cholesteatoma by pathology 
tests were excluded. This research project was approved 
by the Institution’s Ethics Committee and granted permit 
nº. 356/2007.
Auditory involvement was assessed through 
pure-tone and speech audiometry and ranged from mild 
conductive dysacusis to profound sensorineural dysacu-
sis. The extension of the involvement by cholesteatoma 
was analyzed in CT scans and graded based on findings 
such as scutum erosion, erosion of the ossicular chain, 
fistula in the lateral semicircular canal, erosion of the 
tegmen tympani, and Fallopian canal dehiscence. The 
extent of erosion was assessed by the number of invol-
ved structures. Presence of erosion on one structure was 
categorized as +; erosion on two structures was graded 
++; and erosion on three or more structures was rated as 
+++. None of the patients had advanced stage complica-
tions such as facial paralysis, meningitis, encephalitis, or 
brain abscess.
Open mastoidectomy was the approach used to 
remove the cholesteatomas in our group of patients. 
Surgery findings on the extent of involvement and ero-
sion supported the imaging findings on the integrity of 
the middle ear ceiling (tegmen tympani), the wall of 
the lateral semicircular canal, the scutum, and the facial 
canal (Fallopian canal).
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Nineteen suspicious specimens were collected and 
all were confirmed as cholesteatoma by the pathologist. 
The specimens were promptly frozen in liquid nitrogen 
and kept in a freezer at -70°C to maintain messenger 
ribonucleic acid (mRNA) integrity. RNA was isolated 
using Trizol® (Invitrogen) or the Illustra RNAspin® (GE 
Helthcare) kit. RNA quantification was done through UV 
spectrophotometry at 260 nm using device GeneQuant® 
(Amersham-Pharmacia) or by fluorometry in a Qubit® de-
vice (Invitrogen). Total RNA was transformed into com-
plementary DNA (cDNA) by reverse transcription using 
oligonucleotide dT as a primer and enzyme Superscript 
RT III® (Invitrogen). The specific cDNA of each MMP or 
TIMP isoform was amplified by PCR, using reagent mix 
Master Mix (Promega®) and the primers described in the 
literature (glyceraldehyde 3-phosphate dehydrogena-
se - GAPDH21 and MMP2, 3, 9 e 1322) or others picked 
based on their respective mRNA sequences found on 
GenBank (TIMP-1). For more data on primers, please 
refer to Chart 1. The amplification protocol is initialized 
with sample incubation at 94°C for 5 minutes, followed 
by 35 cycles at three temperatures: 94°C for 1 minute 
(denaturation), 58°C for 1 minute (annealing), 72°C for 
1 minute (extension); the last step is incubation at 72°C 
for 10 minutes. PCR products were then separated by 
2% agarose gel electrophoresis (buffer TAE, 100 V) with 
ethidium bromide added as a fluorescent tag. The gel 
images were captured using a digital camera.
RESULTS
The clinical characterization of the cholesteatomas 
of the 19 patients enrolled in the study can be seen in 
Table 1. Patient mean age was 38.7 years (7-67). Most 
of them had right ear cholesteatomas (14/19; 73.7%). CT 
images indicated a wide array of injuries; one patient 
had no erosion, while five had erosion in only one ear 
structure; eight had two compromised structures and five 
had three structures affected by erosion. As for dysacusis, 
most patients had mixed hearing loss.
The first procedure carried out to analyze gene 
expression was the amplification of the mRNA from 
gene GAPDH, assuming that there would be identical 
expression of this enzyme in the glycolytic pathway of all 
analyzed tissue samples. Despite the differences in RNA 
concentration in the samples, higher levels of homogenei-
ty in GAPDH amplification yield were attained when sam-
ple equivalent volume were analyzed (Figure 1). GAPDH 
amplification from the sample collected from patient 9 
was processed in 30, 35, and 40 PCR cycles. At 35 cycles, 
the set condition for amplification used in the study, the 
reaction had not reached saturation.
Chart 1. Characterization of the chosen primer pairs.
GENE PRIMERS
PRODUCT 
SIZE (pb)1
GENBANK2 
REFERENCE OR 
ACCESS NUMBER
GAPDH
Sense
5’ AAC GGG AAG 
CTC ACT GGC 
ATG 3´
Antisense
5’ TCC ACC ACC 
CTG TTG CTG 
TAG 3´
378 pb
Theodoro et al. 
200721
MMP-2
Sense
5’ GCG ACA AGA 
AGT ATG GCT TC 3’
Antisense
5’ TGC CAA GGT 
CAA TGT CAG GA 3’
390 pb
Konttinen et al. 
199922
MMP-3
Sense
5’ CTC ACA GAC 
CTG ACT CGG TT 3’
Antisense
5’ CAC GCC TGA 
AGG AAG AGA TG 3’
294 pb
Konttinen et al. 
199922
MMP-9
Sense
5’ CGC AGA CAT 
CGT CAT CCA GT 3’
Antisense
5’ GGA TTG GCC 
TTG GAA GAT GA 3’
406 pb
Konttinen et al. 
199922
MMP-
13
Sense
5’ CTA TGG TCC 
AGG AGA TGA AG 3’
Antisense
5’ AGA GTC TTG 
CCT GTA TCC TC 3’
390 pb
Konttinen et al. 
199922
TIMP-1
Sense
5’ GGT GGG TGG 
ATG AGT AAT GC 3’
Antisense
5’ TGC AGT TTT 
CCA GCA ATG AG 3’
496 pb NM_003254
1 Base pairs.
2 Reference for the primer sequence or access number in the GenBank 
sequence used to choose primer.
RT-PCR was applied to all samples for metallopro-
teinases 2 and 9; only samples 2, 3, and 10 had amplifica-
tion for MMP2, and none had amplification for MMP9 (see 
results on Figure 2A). Samples 2,3,4,10,11,12,13,14,15, 
and 16 were amplified for MMP3, MMP13 and TIMP1; 
clear amplification for TIMP1 and MMP13 was seen in 
samples 2, 15, 17, and 19, and for MMP3 and TIMP1 
in sample 3 (see Figure 2B). Some reactions were not 
successful due to limited availability of RNA and tech-
nical difficulties in processing small highly keratinized 
samples. The results for MMP and TIMP amplification 
can be seen on Table 1.
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Table 1. Cholesteatoma clinical features and MMP and TIMP gene expression.
Patient Age (years) Dysacusis Erosion MMP-2 MMP-3 MMP-13 TIMP-1
1 12 Mild conductive - - nt nt nt
2 27 Severe mixed +++ +++ - + ++
3 46 Mild conductive + +++ + - +
4 30 Severe mixed + - - - -
5 7 Moderate conductive +++ - nt nt nt
6 52 Severe mixed ++ - nt nt nt
7 54 Profound mixed ++ - nt nt nt
8 58 Moderate mixed +++ - nt nt nt
9 17
Moderate sensori-
neural
++ - nt nt nt
10 42 Moderate conductive + + - - -
11 45 Severe mixed ++ - - - -
12 37 Moderate conductive ++ - - - -
13 67 Severe mixed +++ - - - -
14 42 Moderate conductive + - - - -
15 14 Moderate conductive + - - ++ -
16 42 Moderate conductive +++ - - - -
17 27 Mild conductive ++ - nt ++ nt
18 63 Severe mixed ++ - nt nt nt
19 43 Moderate conductive ++ - nt + nt
nt: not tested.
Figure 1. GAPDH amplification using the volumes fixed for RNA 
preparations. Analysis by 2% agarose gel electrophoresis dyed with 
ethidium bromide. Molecular weight standard = 100 bp ladder. P1-
P14: patients 1 to 14.
Figure 2. MMP and TIMP isoform amplification for selected samples. 
Analysis by 2% agarose gel electrophoresis dyed with ethidium bro-
mide. Molecular weight standard = 100 bp ladder. (A) MMP-2 and 
MMP-9 for samples P2 and P3. (B) MMP-3, MMP-13, and TIMP-1 for 
samples P2, P3, and P4.
DISCUSSION
Chronic cholesteatomatous otitis media is still a 
relevant public health concern in developing countries. 
It is an aggressive benign inflammatory disease that 
may evolve to hearing impairment as it compromises 
soft tissue, bone liners, ossicles and invades adjacent 
structures such as nerves, blood vessels, the cochlea, 
the labyrinth, and the brain.
The presence of MMPs and their inhibitors may 
be associated with higher levels of cholesteatoma-related 
lysis. RT-PCR may aid in the analysis of the expression 
of MMPs and their inhibitors and in the establishment 
of correlation between molecular activity and disease 
aggressiveness. Once such correlation is confirmed, it will 
be possible to propose strategies to control the disease’s 
biochemical development. Some studies have found po-
sitive correlations between cholesteatoma aggressiveness 
and increased levels of MMP25 and MMP910,23, given the 
way these enzymes operate biologically. MMP inhibition 
is being tested as a therapy for various ENT disorders24; 
however, in a pioneering study that looked into treating 
cholesteatomas in animal models with MMP-inhibitor 
ilomastat, disease progression remained unaffected25.
Our study found high levels of MMP2 expression 
in samples 2 and 3, and lower intensity expression in 
sample 10. Contrary to what various other authors have 
found7,10,13,23, enzyme MMP9 was negative for all samples 
in our trial. It should be noted that the MMP9 primer 
pair amplifies human RNA22. Additionally to MMP2, gene 
expression was found for MMP3 (sample 3), MMP13 
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(samples 2, 15, 17, and 19), and TIMP1 (samples 2 and 
3). Presence of MMP3, MMP13, and TIMP1 in choleste-
atoma cells had been reported previously3,16,13.
Despite the progress observed in nucleic acid 
analysis techniques, only two papers in the specific lite-
rature have used RT-PCR to look into gene expression 
of MMPs and their inhibitors. The lack of papers on the 
presence of MMP and TIMP mRNA in cholesteatomas 
may be explained by the technical difficulties inherent 
to processing RNA from cholesteatoma specimens also 
experienced in this study.
The detection of MMP isoenzymes by histochemis-
try or RT-PCR does not imply that the enzymes are active, 
as metalloproteinases are synthesized in an inactive form. 
They become active catalysts only after partial proteoly-
sis, i.e., they are zymogens10. MMP enzymatic activity in 
biologic samples is verified in a laboratory setting through 
separation by electrophoresis followed by gel hydrolysis 
in a technique called zymography. This is a complex 
standardization technique, fraught with conflicting results 
from different research groups. Such issue was obser-
ved for MMP2, as the zymograms in two papers failed 
to verify increased enzymatic activity in cholesteatoma 
fragments10,26, while more recent studies carried out by 
three other groups detected gelatinolytic activity in the 
isoenzyme1,8,16. Controversy also looms over MMP9 analy-
sis: increased activity was reported in two studies8,10 and 
baseline activity in one other paper13. Additionally to these 
two isoforms, MMP1 and MMP3 activity in cholesteatomas 
were also assessed through zymography, and increased 
activity was seen only in the first isoenzyme13.
A literature review on MMP alteration in choles-
teatomas reveals that there still is much to be explored 
in characterizing these enzymes as disease markers. The 
use of RT-PCR with such end has been almost comple-
tely disregarded until recently. This technique could 
be further utilized to quickly analyze the various yet 
unexplored isoforms from the MMP family that could 
have altered expression in cholesteatomas. And TIMP 
inhibitors have been barely studied to date, despite their 
role in controlling MMP activity.
Gene expression analysis by RT-PCR of matrix 
metalloproteinases and their inhibitors offers significant 
technical difficulties. Studies comprising larger numbers 
of patients or considering a greater number of variables 
might allow for stronger clinical correlations with the 
expression of these genes in cholesteatomas.
CONCLUSION
Gene expression of matrix metalloproteinases 
and their inhibitors has been verified in cholesteatomas. 
RT-PCR detected mRNA in MMP2, MMP3, MMP3, and 
TIMP1, but not in MMP9. However, differences in MMP 
and TIMP expression associated with disease aggressi-
veness were not found.
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